Threshold-Based Insulin-Pump Interruption for Reduction of Hypoglycemia
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The threshold-suspend feature of sensor-augmented insulin pumps is designed to minimize the risk of hypoglycemia by interrupting insulin delivery at a preset sensor glucose value. We evaluated sensor-augmented insulin-pump therapy with and without the threshold-suspend feature in patients with nocturnal hypoglycemia. METHODS: We randomly assigned patients with type 1 diabetes and documented nocturnal hypoglycemia to receive sensor-augmented insulin-pump therapy with or without the threshold-suspend feature for 3 months. The primary safety outcome was the change in the glycated hemoglobin level. The primary efficacy outcome was the area under the curve (AUC) for nocturnal hypoglycemic events. Two-hour threshold-suspend events were analyzed with respect to subsequent sensor glucose values. RESULTS: A total of 247 patients were randomly assigned to receive sensor-augmented insulin-pump therapy with the threshold-suspend feature (threshold-suspend group, 121 patients) or standard sensor-augmented insulin-pump therapy (control group, 126 patients). The changes in glycated hemoglobin values were similar in the two groups. The mean AUC for nocturnal hypoglycemic events was 37.5% lower in the threshold-suspend group than in the control group (980 ± 1200 mg per deciliter [54.4 ± 66.6 mmol per liter] × minutes vs. 1568 ± 1995 mg per deciliter [87.0 ± 110.7 mmol per liter] × minutes, P<0.001). Nocturnal hypoglycemic events occurred 31.8% less frequently in the threshold-suspend group than in the control group (1.5 ± 1.0 vs. 2.2 ± 1.3 per patient-week, P<0.001). The percentages of nocturnal sensor glucose values of less than 50 mg per deciliter (2.8 mmol per liter), 50 to less than 60 mg per deciliter (3.3 mmol per liter), and 60 to less than 70 mg per deciliter (3.9 mmol per liter) were significantly reduced in the threshold-suspend group (P<0.001 for each range). After 1438 instances at night in which the pump was stopped for 2 hours, the mean sensor glucose value was 92.6 ± 40.7 mg per deciliter (5.1 ± 2.3 mmol per liter). Four patients (all in the control group) had a severe hypoglycemic event; no patients had diabetic ketoacidosis. CONCLUSIONS: This study showed that over a 3-month period the use of sensor-augmented insulin-pump therapy with the threshold-suspend feature reduced nocturnal hypoglycemia, without increasing glycated hemoglobin values. (Funded by Medtronic MiniMed; ASPIRE ClinicalTrials.gov number, NCT01497938.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“People with diabetes who continue to have frequent and severe hypoglycemia and/or impaired awareness of hypoglycemia, despite educational interventions, may benefit from continuous subcutaneous insulin infusion (CSII) therapy or continuous glucose monitoring (CGM) or both (i.e. a sensor augmented pump), to reduce the risk of severe hypoglycemia (44)(45)(46)(47).”
From Hypoglycemia (2018) · cites this paper as [46]
In the citing paper
“Insulin pumps with automated low-glucose suspend and automated insulin delivery systems have been shown to be effective in reducing hypoglycemia in type 1 diabetes (126).”
From 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. (2026) · cites this paper as [126]
In the citing paper
“Reduction of nocturnal hypoglycemia in individuals with type 1 diabetes using insulin pumps with CGM is improved by automatic suspension of insulin delivery at a preset glucose level, with further improvements when using devices with predictive low-glucose insulin delivery suspension (24,25).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [24]
In the citing paper
“CGM with automated low glucose suspend and hybrid closed-loop systems have been shown to be effective in reducing hypoglycemia in type 1 diabetes (95).”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [95]
Citations
Cites
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Peoples, T., Perkins, B. A., Welsh, J. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002853 · Cited by 894
Self-citationHypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
Cryer, P. (2002) · Diabetologia · doi:10.1007/s00125-002-0822-9 · Cited by 794
Fear of hypoglycemia: quantification, validation, and utilization
Cox, D. J., Irvine, A., Gonder-Frederick, L., Nowacek, G., & Butterfield, J. (1987) · Diabetes Care · doi:10.2337/diacare.10.5.617 · Cited by 579
Mechanisms of Hypoglycemia-Associated Autonomic Failure and Its Component Syndromes in Diabetes
Cryer, P. E. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3592 · Cited by 401
Adaptive increase in sample size when interim results are promising: a practical guide with examples
Mehta, C. R., & Pocock, S. J. (2011) · Statistics in Medicine · doi:10.1002/sim.4102 · Cited by 367
Towler, D. A., Havlin, C. E., Craft, S., & Cryer, P. (1993) · Diabetes · doi:10.2337/diab.42.12.1791 · Cited by 258
Tanenberg, R. J., Newton, C. A., & Drake, A. J. (2010) · Endocrine Practice · doi:10.4158/ep09260.cr · Cited by 225
Increasing the sample size when the unblinded interim result is promising
Chen, Y. H. J., DeMets, D. L., & Gordon Lan, K. K. (2004) · Statistics in Medicine · doi:10.1002/sim.1688 · Cited by 207
Hypoglycemia in Type 1 Diabetes Mellitus
Cryer, P. E. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.05.003 · Cited by 205
Cited by
Items 201–300 of 662
The Accuracy and Efficacy of the Dexcom G4 Platinum Continuous Glucose Monitoring System
Nakamura, K., & Balo, A. K. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815577812 · Cited by 51
“Reports have shown that patients using a modified CGM system in conjunction with an insulin pump can significantly reduce their nocturnal hypoglycemia.(11,12) Patients using CGM have better information to make better diabetes treatment decisions than ever before.”
BackgroundResultAleppo, G., & Webb, K. M. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0097 · Cited by 44
Thieu, V. T., Mitchell, B. D., Varnado, O. J., & Frier, B. M. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13941 · Cited by 44
“The use of continuous subcutaneous insulin infusion with insulin pumps has shown that the frequency of hypoglycaemia can be reduced,(30) and increasing sophistication with the addition of insulin suspension has further lowered the risk of severe hypoglycaemia.(31,32) Dogs that have been trained to identify the onset o…”
BackgroundNew and Emerging Technologies in Type 1 Diabetes
Sherwood, J. S., Russell, S. J., & Putman, M. S. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.07.006 · Cited by 49
“The earliest approved AID systems used threshold suspend, in which insulin delivery way automatically suspended when blood glucose level dropped less than a certain threshold.(29) Predictive glucose suspend improves on this feature by suspending insulin delivery when a hypoglycemic event is predicted in the future.”
BackgroundBeck, R. W., Raghinaru, D., Wadwa, R. P., Chase, H. P., Maahs, D. M., Buckingham, B. A., & for the In Home Closed Loop Study Group (2014) · Diabetes Care · doi:10.2337/dc13-2775 · Cited by 44
Vigersky, R. A., Shin, J., Jiang, B., Siegmund, T., McMahon, C., & Thomas, A. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817718561 · Cited by 47
“The STAR 3 and ASPIRE In-Home trials have been previously described in detail.(17,18) Briefly, in the STAR 3 trial, 495 adults and children were randomized to therapy with multiple daily injections (MDI) and glucose monitoring by fingerstick-obtained blood samples or continuous subcutaneous insulin infusion with gluco…”
Artificial Pancreas: Current Progress and Future Outlook in the Treatment of Type 1 Diabetes
Ramli, R., Reddy, M., & Oliver, N. S. (2019) · Drugs · doi:10.1007/s40265-019-01149-2 · Cited by 48
Kang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 83
Roze, S., Smith‐Palmer, J., Valentine, W. J., Cook, M., Jethwa, M., de Portu, S., & Pickup, J. C. (2015) · Journal of Medical Economics · doi:10.3111/13696998.2015.1113979 · Cited by 42
Closed loop insulin delivery in diabetes
Battelino, T., Omladič, J. Š., & Phillip, M. (2015) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2015.03.001 · Cited by 42
Reddy, M., Herrero, P., El-Sharkawy, M., Pesl, P., Jugnee, N., Pavitt, D. V., Godsland, I. F., Alberti, K. G. M. M., Toumazou, C., Johnston, D. G., et al. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815616134 · Cited by 51
“The combination of sensor and CSII in sensor-augmented pump therapy with the low-glucose suspend feature has been reported to improve HbA1c and reduce hypoglycemia.(4,5) The next step in diabetes technology is the artificial pancreas, comprising a subcutaneous glucose sensor, control algorithm to calculate insulin inf…”
MethodReimbursement for Continuous Glucose Monitoring
Heinemann, L., & DeVries, J. H. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0296 · Cited by 40
“ASPIRE confirmed that sensor-augmented pump/low glucose suspend diminishes time in hypoglycemia.(10,12,13) Whereas these studies did not report a reduction in severe hypoglycemic events, a recently reported study from Australia did so, focusing on patients with hypoglycemia unawareness.”
ResultNimri, R., Bratina, N., Kordonouri, O., Stefanija, M. A., Fath, M., Biester, T., Muller, I., Atlas, E., Miller, S., Fogel, A., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12852 · Cited by 42
Cichosz, S. L., Jensen, M. H., & Hejlesen, O. K. (2021) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2021.104472 · Cited by 45
Glycemic Management in Adults With Type 1 Diabetes
McGibbon, A., Adams, L., Ingersoll, K. S., Kader, T., & Tugwell, B. D. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.012 · Cited by 58
Agrawal, P. K., Zhong, A., Welsh, J. B., Shah, R. V., & KAUFMAN, F. R. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0257 · Cited by 40
Self-citationA Review of Safety and Hazards Associated With the Artificial Pancreas
Ramkissoon, C. M., Aufderheide, B., Bequette, B. W., & Vehí, J. (2017) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2017.2749038 · Cited by 46
“[103], whereas PLGS suspends insulin infusion if hypoglycemia is predicted to occur within 30 min and resumes insulin delivery when BG levels begin to rise [104].”
BackgroundGlucose-responsive insulin delivery for type 1 diabetes: The artificial pancreas story
Bally, L., Thabit, H., & Hovorka, R. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.12.022 · Cited by 43
Hypoglycaemia unawareness in patients with type 1 diabetes
Szadkowska, A., Czyżewska, K., Pietrzak, I., Mianowska, B., Jarosz-Chobot, P. A., & Myśliwiec, M. (2018) · Pediatric Endocrinology Diabetes and Metabolism · doi:10.5114/pedm.2018.80994 · Cited by 46
Real-World Data from the First U.S. Commercial Users of an Implantable Continuous Glucose Sensor
Sanchez, P., Ghosh-Dastidar, S., Tweden, K. S., & Kaufman, F. R. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0234 · Cited by 40
“18 Hybrid closed loop systems have reported variable TIR, with the first commercial product, the MiniMed (cid”
Self-citationContinuous Glucose Monitoring: Impact on Hypoglycemia
van Beers, C. A. J., & DeVries, J. H. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816653411 · Cited by 46
“In 2013, the ASPIRE In-Home Study Group evaluated the effect of SAPT with LGS, compared with SAPT alone, on nocturnal hypoglycemia and glycated hemoglobin levels.(33) Patients were eligible if they experienced ≥2 nocturnal hypoglycemic events during the 2-week run-in phase.”
BackgroundMethodAbraham, M. B., Davey, R., O'Grady, M. J., Ly, T. T., Paramalingam, N., Fournier, P. A., Roy, A., Grosman, B., Kurtz, N., Fairchild, J. M., et al. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0141 · Cited by 40
“:3) system) suspends basal insulin infusion when the preset sensor hypoglycemic threshold is reached and reduces the depth and duration of nocturnal hypoglycemia 6,7 without an increase in ketosis.”
Abitbol, A., RABASA-LHORET, R. P. R., Messier, V., Legault, L., Smaoui, M. R., Cohen, N., & Haidar, A. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0353 · Cited by 40
Going beyond HbA1c to understand the benefits of advanced diabetes therapies
Vigersky, R. A. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12846 · Cited by 42
Hermanns, N., Schumann, B., Kulzer, B., & Haak, T. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814524105 · Cited by 39
Calhoun, P. M., Buckingham, B. A., Maahs, D. M., HRAMIAK, I. M., Wilson, D. M., Aye, T., Clinton, P. K., Chase, P., Messer, L. H., Kollman, C., et al. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816645119 · Cited by 39
“Many studies utilize a warm-up period(13,14) or have patients wear the system continuously.(15) Further research is warranted to assess whether continuously worn systems are more effective in the early part of the night.”
BackgroundEmbedded Control in Wearable Medical Devices: Application to the Artificial Pancreas
Zavitsanou, S., Chakrabarty, A., Dassau, E., & Doyle, F. J. (2016) · Processes · doi:10.3390/pr4040035 · Cited by 44
“A low-glucose suspend system includes a threshold-suspend feature of sensor-augmented insulin pumps that forces the pump to shut off when CGM values drop below a certain threshold [48].”
BackgroundLucidi, P., Porcellati, F., Bolli, G. B., & Fanelli, C. G. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1065-6 · Cited by 38
Roze, S., Smith-Palmer, J., Valentine, W., Payet, V., de Portu, S., Papo, N., Cucherat, M., & Hanaire, H. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0224 · Cited by 37
“In particular, in the ASPIRE study, the use of the LGS feature was shown to lead to a significant reduction in the incidence of nocturnal hypoglycemia in hypoglycemia-prone patients.(7) In the present analysis, the cost-effectiveness of SAP + LGS versus standard CSII alone was compared in two separate patient cohorts.”
Automatic adaptation of basal therapy for Type 1 diabetic patients: A Run-to-Run approach
Toffanin, C., Messori, M., Cobelli, C., & Magni, L. (2016) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2016.09.002 · Cited by 37
“The availability of Continuous Glucose Monitoring (CGM) and subcutaneous insulin infusion allows to improve glycemic control based on the so-called sensor-augmented insulin-pump therapy [3,4], i.”
BackgroundRecent Updates on Type 1 Diabetes Mellitus Management for Clinicians
Iqbal, A., Novodvorský, P., & Heller, S. R. (2018) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.42.1.3 · Cited by 45
Real-World Implications of Hybrid Close Loop (Hcl) Insulin Delivery System
Faulds, E. R., Zappe, J., & Dungan, K. M. (2019) · Endocrine Practice · doi:10.4158/ep-2018-0515 · Cited by 37
“The earliest systems demonstrated reduced frequency of hypoglycemia via automated suspension of insulin delivery in response to actual or predicted low sensor glucose (15,16).”
BackgroundResultMCVEAN, J. J. F., & Miller, J. D. (2021) · Expert Review of Medical Devices · doi:10.1080/17434440.2021.1926984 · Cited by 38
“in HbA1c over the 3-month study between the control group and the group using threshold suspend [11].”
MethodClosed-loop for type 1 diabetes – an introduction and appraisal for the generalist
Bally, L., Thabit, H., & Hovorka, R. (2017) · BMC Medicine · doi:10.1186/s12916-017-0794-8 · Cited by 38
Garg, S. K., & Aktürk, H. K. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0142 · Cited by 37
“50 51–53 The first system known as hybrid-closed loop (artificial pancreas) was approved by the FDA in September 2016.”
Self-citationAbraham, M. B., de Bock, M. I., Paramalingam, N., O'Grady, M. J., Ly, T. T., George, C., Roy, A., Spital, G., Karula, S., Heels, K., et al. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0364 · Cited by 36
“This function reduces moderate and severe episodes of hypoglycemia in patients with impaired awareness of hypoglycemia(6) and suspension of insulin delivery is not associated with rebound hyperglycemia and ketosis or significant changes in glycated hemoglobin.(7,8) The development of an algorithm that predicts impendi…”
Diagnosis, Therapy and Follow-up of Diabetes Mellitus in Children and Adolescents
Neu, A., Bürger-Büsing, J., Danne, T., Dost, A., Holder, M., Holl, R. W., Holterhus, P., Kapellen, T. M., Karges, B., Kordonouri, O., et al. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0869-0210 · Cited by 38
“[48] Bergenstal RM, Klonoff DC, Garg SK, Bode BW, Meredith M, Slover RH, Ahmann AJ, Welsh JB, Lee SW, Kaufman FR.”
BackgroundHering, B. J., & O’Connell, P. J. (2016) · Xenotransplantation · doi:10.1111/xen.12228 · Cited by 37
“The same technology, SAP with LGS, when compared in a randomized clinical trial with SAP without LGS, reduced nocturnal hypoglycemia without increasing glycated hemoglobin values; patients were excluded if they had more than one SHE in the previous 6 months [29].”
MethodSherr, J. L., Palau Collazo, M., Cengiz, E., Michaud, C., Carria, L., Steffen, A. T., Weyman, K., Zgorski, M., Tichy, E., Tamborlane, W. V., et al. (2014) · Diabetes Care · doi:10.2337/dc13-1608 · Cited by 35
Utility of Continuous Glucose Monitoring in Type 1 and Type 2 Diabetes
Toschi, E., & Wolpert, H. A. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.06.003 · Cited by 41
“Studies have shown that the use of SIP technology in T1DM can improve both glucose control and, if using a low glucose threshold suspend, can reduce hypoglycemic events.(32,33) Suc-”
BackgroundManagement of Hypoglycemia in Children and Adolescents with Type 1 Diabetes Mellitus
McGill, D. E., & Levitsky, L. L. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0771-1 · Cited by 39
Technological advances shaping diabetes care
Aktürk, H. K., & Garg, S. K. (2019) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000467 · Cited by 35
Self-citationBassi, M., Franzone, D., Dufour, F., Strati, M. F., Scalas, M., Tantari, G., Aloi, C., Salina, A., d’Annunzio, G., Maghnie, M., et al. (2023) · Life · doi:10.3390/life13030783 · Cited by 46
“Subsequently, SAPs were developed with the LGS (Low Glucose Suspend) function, capable of automatically interrupting the basal insulin infusion in case of hypoglycemia, and SAPs with the PLGS (Predictive Low Glucose Suspend) function, which consists of suspending basal insulin delivery in case of hypoglycemia and pred…”
MethodElian, V., Popovici, V., Ozon, E.-A., Musuc, A. M., Fița, A. C., Rusu, E., Radulian, G., & Lupuliasa, D. (2023) · Life · doi:10.3390/life13081663 · Cited by 41
Jacobsen, L. M., Sherr, J. L., Considine, E. G., Chen, A. X., Peeling, S., Hulsmans, M., Charleer, S., Urazbayeva, M., Tosur, M., ALAMARIE, S. A., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00358-x · Cited by 40
Artificial pancreas: fuzzy logic and control of glycemia
Nimri, R., & Phillip, M. (2014) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000073 · Cited by 37
Mariani, H., Layden, B. T., & Aleppo, G. (2017) · Clinical Diabetes · doi:10.2337/cd16-0008 · Cited by 37
Hanazaki, K., Munekage, M., Kitagawa, H., Yatabe, T., Munekage, E., Shiga, M., Maeda, H., & Namikawa, T. (2016) · Journal of Artificial Organs · doi:10.1007/s10047-016-0904-y · Cited by 35
“Recent large studies supported these findings in type 1 diabetic patients suffering nocturnal hypoglycemic events, although the automatic suspension of insulin delivery could not completely prevent hypoglycemia [3, 4].”
ResultAutomated Insulin Delivery in Adults
Boughton, C. K., & Hovorka, R. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.10.007 · Cited by 34
Gómez, A. M., Carrillo, L. F. M., Múñoz, Ó., Rondón, M., Correa, C. M. A., Garzón, E. M., Diaz, M. C. C., & Henao, D. C. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0332 · Cited by 32
Hypoglycaemia in type 1 diabetes mellitus: risks and practical prevention strategies
Kaur, J., & Seaquist, E. R. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00762-8 · Cited by 38
Biswas, T., Behera, B. K., & Madhu, N. R. (2023) · Springer eBooks · doi:10.1007/978-981-19-0027-3_6 · Cited by 33
Hypo- and Hyperglycemic Alarms: Devices and Algorithms
Howsmon, D. P., & Bequette, B. W. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815583507 · Cited by 35
“A recent retrospective analysis of the LGS feature of the MiniMed 530G in > 20 000 patients over a 40-week period also shows decreased exposure to hypoglycemia without increase in hyperglycemia.(121) Just as highly accurate threshold alarms paved the way for LGS systems, predictive alarms have led to predictive low gl…”
BackgroundCurrent Trends in Continuous Glucose Monitoring
Lodwig, V., Kulzer, B., Schnell, O., & Heinemann, L. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814525826 · Cited by 32
Renard, E., Tubiana‐Rufi, N., Bonnemaison‐Gilbert, E., Coutant, R., Dalla‐Vale, F., Farret, A., Poidvin, A., Bouhours‐Nouet, N., Abettan, C., Storey‐London, C., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13482 · Cited by 31
“Commercially available sensor-augmented pump therapy (SAP) with automated stopping of insulin infusion when continuous glucose monitoring (CGM) reaches a predefined glucose threshold [thresholdlow-glucose-suspend (TLGS)] has shown significant reduction of time in hypoglycaemia.(2,3) Investigational control-to-range (C…”
ResultSlover, R. H., Tryggestad, J. B., DiMeglio, L. A., Fox, L. A., Bode, B. W., Bailey, T. S., Brazg, R., Christiansen, M. P., Sherr, J. L., Tsalikian, E., et al. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0109 · Cited by 37
Self-citationWood, M. A., Shulman, D. I., Forlenza, G. P., Bode, B. W., Pinhas‐Hamiel, O., Buckingham, B. A., Kaiserman, K. B., Liljenquist, D. R., Bailey, T. S., Shin, J., et al. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0209 · Cited by 32
Self-citationVerbeeten, K. C., Trejo, M. E. P., Tang, K., Chan, J., Courtney, J. M., Bradley, B., McAssey, K., Clarson, C. L., Kirsch, S. E., Curtis, J. R., et al. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13150 · Cited by 32
Devices for continuous monitoring of glucose: update in technology
Gómez, A. M., Carrillo, D. C. H., & Múñoz, Ó. (2017) · Medical Devices Evidence and Research · doi:10.2147/mder.s110121 · Cited by 34
Martin, C., Criego, A. B., Carlson, A. L., & Bergenstal, R. M. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1177-7 · Cited by 34
Self-citationAdvances in Exercise, Physical Activity, and Diabetes Mellitus
Pasieka, A. M., Nikoletos, N., & Riddell, M. C. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.2508 · Cited by 31
Joshi, M., & Choudhary, P. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0644-z · Cited by 32
Thabit, H., Elleri, D., Leelarathna, L., Allen, J. M., Lubina-Solomon, A., Stadler, M., Walkinshaw, E., Iqbal, A., Choudhary, P., Wilinska, M. E., et al. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12427 · Cited by 31
“Its application reduces nocturnal frequency and duration of hypoglycaemia [21,22], but is unable to step up insulin delivery during episodes of elevated glucose levels and does not alter overall glucose control [22].”
BackgroundPsychosocial Aspects of Diabetes Technology
Polonsky, W. H. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.10.003 · Cited by 29
Petrovski, G., Khalaf, F. A., Campbell, J., Fisher, H., Umer, F., & Hussain, K. (2020) · Acta Diabetologica · doi:10.1007/s00592-019-01472-w · Cited by 32
“Insulin delivery suspension when reaching a low glucose level [3, 4] or in prediction of a low glucose level [5, 6] has demonstrated significant reduction in hypoglycemia exposure.”
BackgroundHypoglycemia Begets Hypoglycemia: The Order Effect in the ASPIRE In-Clinic Study
Garg, S. K., Brazg, R., Bailey, T. S., Buckingham, B. A., Slover, R. H., Klonoff, D. C., Shin, J., Welsh, J. B., & KAUFMAN, F. R. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0219 · Cited by 31
“11 The ASPIRE in-clinic study’s crossover design allowed comparison of subjects’ recovery from hypoglycemia under various conditions and showed that recent hypoglycemia is detrimental to recovery from subsequent hypoglycemia.”
Self-citationBouchonville, M. F., Jaghab, J. J., Duran-Valdez, E., Schrader, R., & Schade, D. S. (2014) · Endocrine Practice · doi:10.4158/ep14198.or · Cited by 29
Mitsuishi, S., Nishimura, R., Harashima, S., Kawamura, T., Tsujino, D., Koide, K., Nishimura, A., Utsunomiya, K., Inagaki, N., & Atsumi, Y. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0649-x · Cited by 28
“monitoring tools or technologies, including insulin-suspended technology [21].”
BackgroundMethodRecent advances in closed-loop insulin delivery
Ware, J., & Hovorka, R. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154953 · Cited by 31
Hybrid Closed Loop Using a Do-It-Yourself Artificial Pancreas System in Adults With Type 1 Diabetes
Nanayakkara, N., Sharifi, A., Burren, D., Elghattis, Y., Jayarathna, D. K., & Cohen, N. D. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231153882 · Cited by 28
Chen, E., King, F., Kohn, M. A., Spanakis, E. K., Breton, M. D., & Klonoff, D. C. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0119 · Cited by 28
“7,8 To safely reduce hypoglycemia, a more sophisticated approach has been developed.”
Self-citationIslet Cell Transplantion: Update on Current Clinical Trials
Schuetz, C., & Markmann, J. F. (2016) · Current Transplantation Reports · doi:10.1007/s40472-016-0103-z · Cited by 34
Alotaibi, A., Khalifah, R. A. A., & McAssey, K. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13088 · Cited by 27
“However, the hypoglycemia fear survey did not show any difference after 3 months.(5) Two RCTs included in our meta-analysis enrolled adults with type 1 diabetes in addition to pediatric and adolescent participants.”
BackgroundMethodBoscari, F., Ferretto, S., Cavallin, F., & Bruttomesso, D. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109784 · Cited by 27
A New Horizon for Glucose Monitoring
Dovč, K., Bratina, N., & Battelino, T. (2015) · Hormone Research in Paediatrics · doi:10.1159/000368924 · Cited by 30
Update on Clinical Utility of Continuous Glucose Monitoring in Type 1 Diabetes
Haviland, N., Walsh, J. S. A., Roberts, R., & Bailey, T. S. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0808-5 · Cited by 29
Urakami, T., Yoshida, K., Kuwabara, R., Mine, Y., Aoki, M., Suzuki, J., & Morioka, I. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13618 · Cited by 26
Bakhtiani, P. A., Youssef, J. E., Duell, A. K., Branigan, D. L., Jacobs, P. G., Lasarev, M. R., Castle, J. R., & Ward, W. K. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.09.001 · Cited by 28
“Most closed-loop systems only deliver the hormone insulin (11,12).”
BackgroundFrommeyer, T. C., Fursmidt, R. M., Gilbert, M. M., & Bett, E. S. (2022) · Frontiers in Digital Health · doi:10.3389/fdgth.2022.831123 · Cited by 25
Escaping the Hemoglobin A1c-Centric World in Evaluating Diabetes Mellitus Interventions
Vigersky, R. A. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815576363 · Cited by 26
“The low glucose threshold suspend pump scores an 80 based on a 31% decrease in severe hypoglycemia, no change in A1c and no change in body weight.(16) A similar score of 80 is obtained in a psychoeducational intervention for those with hypoglycemia unawareness (assuming no weight change) because of a large reduction i…”
BackgroundDevelopment and Future of Automated Insulin Delivery (AID) Systems
Garg, S. K., & MCVEAN, J. J. F. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0467 · Cited by 28
“30,31 A randomized control trial (AS-PIRE study) using the TS insulin pump system for 3 months at home documented a 37% reduction in nocturnal hypo-glycemia when compared with sensor-augmented pump therapy without TS. 29 The first AID system approved in the United States was the MiniMed (cid:2) 670G system, which deliv…”
InfluentialSelf-citationMallad, A., Hinshaw, L., Man, C. D., Cobelli, C., Basu, R., Lingineni, R. K., Carter, R. E., Kudva, Y. C., & Basu, A. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0011 · Cited by 26
Update on the American Diabetes Association Standards of Medical Care
Zitkus, B. S. (2014) · The Nurse Practitioner · doi:10.1097/01.npr.0000451880.48790.50 · Cited by 30
Management of diabetes mellitus in children and adolescents: engaging in physical activity
Nadella, S., Indyk, J. A., & Kamboj, M. K. (2017) · Translational Pediatrics · doi:10.21037/tp.2017.05.01 · Cited by 29
Suzuki, J., Urakami, T., Yoshida, K., Kuwabara, R., Mine, Y., Aoki, M., & Morioka, I. (2020) · Pediatrics International · doi:10.1111/ped.14412 · Cited by 26
A clinical review of the t:slim X2 insulin pump
Berget, C., Lange, S. L., Messer, L. H., & Forlenza, G. P. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1814734 · Cited by 27
Shah, V. N., Moser, E. G., Blau, A., Dhingra, M., & Garg, S. K. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0228 · Cited by 27
Self-citationAnandhakrishnan, A., & Hussain, S. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15920 · Cited by 28
“91 When AID systems targeting hypoglycaemia were compared with SAP, LGS devices were shown to improve hypoglycaemia without increases in HbA1c, 33,92 and PLGS were shown to reduce the severity and duration of hypoglycaemia, 35,93 with resultant QoL benefits in pwT1D.”
Progress of artificial pancreas devices towards clinical use: the first outpatient studies
Russell, S. J. (2015) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000142 · Cited by 28
Müller, L., HABIF, S., LEAS, S. A., & Aronoff-Spencer, E. S. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0190 · Cited by 24
Outpatient Management of Pediatric Type 1 Diabetes
Beck, J. K., & Cogen, F. R. (2015) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-20.5.344 · Cited by 25
Closed-loop insulin delivery: current status of diabetes technologies and future prospects
Majeed, W., & Thabit, H. (2018) · Expert Review of Medical Devices · doi:10.1080/17434440.2018.1503530 · Cited by 27
“Compared to standard SAP, LGS has been shown to significantly reduce nocturnal hypoglycaemia, without increasing HbA1c or ketosis [58].”
MethodOptimal regulation of blood glucose level in Type I diabetes using insulin and glucagon
Shirin, A., Rossa, F. D., Klickstein, I. S., Russell, J. J., & Sorrentino, F. (2019) · PLoS ONE · doi:10.1371/journal.pone.0213665 · Cited by 27
Senior, P. A., & Pettus, J. (2018) · Diabetic Medicine · doi:10.1111/dme.13846 · Cited by 26
Freckmann, G., Schauer, S., Beltzer, A., Waldenmaier, D., Buck, S., Baumstark, A., Jendrike, N. R. M., Link, M., Zschornack, E., Haug, C., et al. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221113341 · Cited by 24
“…the detection of prediabetes using CGM. 29 Likewise, with regard to interoperable CGM systems and insulin pumps, as well as the further development of (hybrid) closed-loop systems 30,31 it is essential to take into account the physiologic level of glycemic control in healthy individuals.”
Backgroundvan den Boom, L., Auzanneau, M., Woelfle, J., Sindichakis, M., Herbst, A., Meraner, D., Hake, K., Klinkert, C., Gohlke, B. C., & Holl, R. W. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231156601 · Cited by 26
Matejko, B., SKUPIEN, J. K., Mrozińska, S., Grzanka, M., Cyganek, K., Kieć‐Wilk, B., Malecki, M. T., & Klupa, T. (2014) · Endocrine · doi:10.1007/s12020-014-0274-2 · Cited by 23
Desjardins, K., Brazeau, A., Strychar, I. M., Leroux, C., Gingras, V., & RABASA-LHORET, R. P. R. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.09.015 · Cited by 29
“In this context, the use of sensoraugmented CSII therapy especially with low glucose suspend function could be useful to reduce NH episodes [9].”
BackgroundInfluentialInsulin pump therapy in youth with type 1 diabetes: toward closed-loop systems
Tauschmann, M., & Hovorka, R. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.910192 · Cited by 24
“When compared to SAP therapy, threshold suspend did not improve QoL [66].”
BackgroundMethodResultInfluentialLablanche, S., David‐Tchouda, S., Margier, J., Schir, É., Wojtusciszyn, A., Borot, S., Kessler, L., Morélon, E., Thivolet, C. H., Pattou, F. N., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013434 · Cited by 23
Metadata
- Authors
- Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R.
- Affiliations
- Park Nicollet Health Services (US)
- Mills Peninsula Health Services (US)
- University of Colorado Denver (US)
- Atlanta Diabetes Associates (US)
- University of Wisconsin–Madison (US)
- Oregon Health & Science University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-18
- Volume
- 369
- Issue
- 3
- Pages
- 224-232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2102877966
- Cited by
- 652
- References
- 21
- Citations by year
- 2026: 7 · 2025: 17 · 2024: 18 · 2023: 36 · 2022: 30 · 2021: 41 · 2020: 39 · 2019: 62 · 2018: 75 · 2017: 80 · 2016: 82 · 2015: 74 · 2014: 73 · 2013: 17
- FWCI
- 64.50
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by-nc
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Repositorio Institucional (Pontificia Universidad Javeriana) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- sensor-augmented pump, insulin pump therapy, nocturnal hypoglycemia, type 1 diabetes, HbA1c, hypoglycemia prevention, continuous glucose monitoring, glycemic control, hypoglycemic events, hypoglycemia severity, hypoglycemia duration
- MeSH terms
- Adolescent, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 1, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Middle Aged, Area Under Curve, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.